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Os2–Os4 Switch Controls DNA Knotting and Anticancer Activity
Ying Fu+, Mara J. Romero+, Luca Salassa, Xi Cheng, Abraha Habtemariam, Guy J. Clarkson,
Ivan Prokes, Alison Rodger, Giovanni Costantini, and Peter J. Sadler*
Abstract: Dinuclear trihydroxido-bridged osmium–arene
complexes are inert and biologically inactive, but we show
here that linking dihydroxido-bridged OsII–arene fragments by
a bridging di-imine to form a metallacycle framework results in
strong antiproliferative activity towards cancer cells and
distinctive knotting of DNA. The shortened spacer length
reduces biological activity and stability in solution towards
decomposition to biologically inactive dimers. Significant
differences in behavior toward plasmid DNA condensation
are correlated with biological activity.
Platinum drugs are used in over 50% of all chemother-
apeutic regimens.[1] The basis for their activity is believed to
be mainly due to DNA binding, in particular to changes in
DNA conformation.[2] Resistance to Pt drugs is a clinical
drawback that might be overcome by designing new drugs
that induce distinctly different conformational changes in
DNA.[3] Multinuclear metal complexes provide a promising
strategy for such an approach.[4]
Herein, we consider the design of multinuclear “piano-
stool” organo-osmium complexes. Half-sandwich OsII arene
complexes exhibit antitumor activity both in vitro and in
vivo.[5] O,O-chelated OsII complexes, such as [(h6-arene)Os-
(acac)Cl], undergo rapid hydrolysis to produce not only the
aqua adduct, [(h6-arene)Os(acac)(OH2)]
+, but also the
hydroxido-bridged dimer, [(h6-arene)Os(m2-OH)3Os(h
6-
arene)]+, which is inactive against cancer cells.[6] Early work
by Fujita et al. , Chi et al. , and Therrien et al. demonstrated
that macrocyclic polynuclear Pt and Ru complexes can have
anticancer activity comparable to cisplatin, possibly through
targeting DNA.[7] However, little is known about the aqueous
stability of polynuclear metallacycles and its effect on
biological activity.
In this work, we link inert biologically inactive dinuclear
hydroxido-bridged OsII arene units to form active tetra-
nuclear complexes that can induce DNA knotting. We show
that the length of the linker is critical for maintaining stability
of the tetranuclear assembly in solution, inducing DNA
binding and enhancing antiproliferative activity towards
human cancer cells. We compare 4,4’-azopyridine (pap) as
a linker with the shorter pyrazine (prz).
Direct addition of either the pap or prz linkers to the
hydroxido intermediate afforded tetranuclear OsII products
[Os4(h
6-p-cym)4(m
2-OH)4(pap)2][PF6]4 (1·[PF6]4) and [Os4(h
6-
p-cym)4(m
2-OH)4(prz)2][PF6]4 (2·[PF6]4). Recrystallization
from CH2Cl2/CH3OH solutions gave single crystals of
1·[PF6]4·2CH2Cl2·CH3OH and 2·[PF6]4·6CH3OH·2H2O,
respectively. The X-ray crystal structures of 1 and 2 are
shown in Figures 1 and S1 (Supporting Information). Crystal
data and selected bond lengths and angles are listed in
Tables S1,S2.
Very few X-ray structures of hydroxido-bridged osmium-
(II) arene complexes have been reported since the early study
Figure 1. X-ray crystal structures of 1 (A) and 2 (B).
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of oxo/hydroxido OsII benzene complexes.[8] The structures of
1·[PF6]4 and 2·[PF6]4 (Figure 1) appear to be the first examples
of organometallic OsII complexes containing arene, m2-
hydroxido, and aromatic N-donor ligands simultaneously. A
detailed description of the structures is in Figure S1. The
distance between the Os atoms bridged by pap is 13.175  (1),
and almost half (6.995 ) with the prz bridge (2). DFT-
optimized geometries are in good agreement with these
structures (Tables S3–S5). UV/Vis absorption spectra were
recorded for 1 and 2 in acetone (Figure S2). Time-dependent
Density Functional Theory (TDDFT) singlet excited state
calculations for both complexes showed that the absorption
band at 435–450 nm has 1MLCT (metal-to-ligand charge-
transfer) character and is composed of two major transitions
involving Os-based occupied orbitals and ligand-based
LUMO and LUMO+ 1 (Figure S2). Notably, MLCT transi-
tions at wavelengths higher than 600 nm are found for 1, in
agreement with the experimental spectrum. The intensity of
such TDDFT transitions is overestimated (particularly the
singlet electronic transition S3), as expected for highly
delocalized systems displaying charge-transfer bands.[9]
The stability of the tetramer 1 in solution was investigated
first in [D6]acetone. The
1H NMR spectra of 1·[PF6]4 at 298 K
showed two singlets at 6.68 and 6.66 ppm assignable as OH
peaks (Figure S3A). This appears to be the first detection of
peaks for bridging-OH groups in organometallic tetranuclear
complexes.[10] To confirm this assignment, 1H NMR at various
temperatures and 2D 1H DOSY NMR spectra were recorded.
The two OH singlets shifted downfield reversibly at lower
temperature (Figure S3 and S4) with a linear temperature
dependence (Dd/DT=0.009 ppmK1). Interestingly, two
peaks assignable to H2O and HOD were also observed in
these [D6]acetone solutions (Figure S5).
[11] When H2O
(10 mL) was added, the H2O and OH bridge peaks shifted
downfield (Figure S6). The two low-field OH peaks disap-
peared upon addition of D2O (Figure S7). The diffusion-
ordered spectroscopy (DOSY) 2D 1H NMR spectrum of
1·[PF6]4 supported assignment of the two singlets (6.68 and
6.66 ppm) to OH bridges (Figure S8). These studies suggested
that both OH bridges are involved in H-bond interactions,
which are strongly dependent on temperature and water
concentration.
The aqueous stabilities of 1·[PF6]4 and 2·[PF6]4 in 10%
MeOD-d4/90% D2O phosphate buffer (1 mm, pH*= 7.4)
were investigated by 1H NMR spectroscopy. After 24 h at
310 K, 63% of cationic 1 was still present as the intact
tetramer, whereas 2 decomposed completely under the same
conditions and the solution became colorless (Figure S9). 2D
1H DOSY experiments on 2·[PF6]4 (Figure 2) confirmed the
release of the aromatic linker with a concomitant breakdown
of the tetranuclear assembly and generation of an hydroxido-
bridged OsII–arene dimer [Os2(h
6-p-cym)2(m
2-OH)3]
+ for both
1 and 2. The formation of this biologically inert hydroxido
dimer[6] was confirmed by ESI-MS (Figure S9).
The antiproliferative activity of 1 and 2 towards cancer
cells was determined. The IC50 value for A2780 human
ovarian cancer cells decreased dramatically from > 100 mm to
10 mm as the linker length increased from pyrazine in complex
2·[PF6]4 to 4,4’-azopyridine in complex 1·[PF6]4 (Table 1). An
analogous trend in antiproliferative activity was observed for
A549 and H596 human non-small-cell lung cancer (NSCLC)
cell lines (Table 1). In these two cell lines, 1·[PF6]4 showed
similar anticancer potency to cisplatin and was approximately
2-times more potent than 2·[PF6]4. No antiproliferative
activity was observed for the free linker ligands. The highest
antiproliferative activity is therefore associated with the
cationic complex that more readily retains its tetranuclear
structure in solution (complex 1). The anticancer activity of
2·[PF6]4 is comparable to some reported dinuclear Ru
II
cylinders.[12]
Metallosupramolecules are also known to bind in the
grooves of DNA.[13] Therefore, binding of complexes 1 and 2
to calf thymus DNA (ct-DNA) was also investigated (Fig-
ures S11 and S13). The characteristic circular dichroism (CD)
bands of ct-DNA (Figure S11) and the negative linear
dichroism (LD) band arising from the DNA bases (Fig-
ure S13) decreased in intensity with increasing concentrations
of 1 or 2, even at low Os loading. Red fibers, likely
corresponding to DNA-tetramer adducts, were observed at
high Os loading (Figure S12). These data suggest that both
OsII tetramers bind to ct-DNA and induce DNA condensa-
tion, facilitated by their 4+ charge, but more significantly for
tetramer 1.
Figure 2. 2D DOSY 1H NMR study of the stability of complex 2·[PF6]4
in buffered aqueous solution (see the Supporting Information);
t= time point at which spectra were recorded.
Table 1: Cytotoxicity (IC50, mm) of 1·[PF6]4 and 2·[PF6]4 towards A549
(lung), H596 (lung), and A2780 (ovarian) human cancer cell lines.
Complex A549 H596 A2780
CDDP 6.7(0.6) 5.9(1.4) 1.8(0.1)
1 5.2(0.3) 4.8(2.0) 10.1(0.1)
2 12.9(2.2) 10.8(1.3) >100
Angewandte
ChemieCommunications
2 www.angewandte.org  2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2016, 55, 1 – 5

These are not the final page numbers!
Further insight into OsII tetramer–DNA interactions was
obtained using tapping mode atomic force microscopy (AFM)
(Figures 3 and S14). AFM images were recorded at two
different time points, 30 min after preparing the samples and
24 h after incubation at 310 K. Figure 3a,b shows images of
the control sample where the free pBR322 plasmid was
deposited onto freshly cleaved mica treated with Mg2+ to
ensure firm adsorption of the negatively charged DNA.
Mainly relaxed open circular (OC) and linear (L) forms were
observed on the surface after the free plasmid relaxation
procedure (Supporting Information). Analysis of cross sec-
tions of the different forms resulted in comparable heights of
0.70 0.08 nm (OC) and 0.70 0.10 nm (L; Figure 3a,b).
These values are smaller than the theoretical DNA diameter
(ca. 2 nm), probably owing to electrostatic interactions with
the positively charged mica surface that tend to compress the
plasmids.[14]
Figures 3c,d and S14 show the effect of interactions
between plasmid DNA and complexes 1 or 2 at a DNA
base:Os4 ratio of 5:1. No plasmids were detected on any of the
analyzed samples after mixing with the more biologically
active tetramer 1·[PF6]4 (Figure S14a,b). This was interpreted
as an indication that the DNA forms an adduct with cationic
tetramer 1, thus becoming less negatively charged and less
strongly bound to the positively charged mica substrate.
Interaction with the less biologically active tetramer
2·[PF6]4 gave rise to the formation of knotted aggregates of
plasmid DNA, appearing as plasmid loops emerging from
a condensed nucleus, probably generated by the linking of
several DNA strands mediated by 2 (Figure 3c). The DNA
adducts with complex 2 were strongly attached to the Mg2+-
treated surface. This suggests a larger negative charge density
of DNA-2 with respect to DNA-1 adducts, probably owing to
a reduced number of bound molecules of 2 with respect to 1.
A cross-sectional height analysis confirmed this conclusion
(Figure S14, detailed discussion in the Supporting Informa-
tion). This is the first report on the formation of this type of
DNA aggregate with organo-osmium anticancer complexes.
The unusual behavior of 1 and 2 differs considerably from the
DNA cross-linking caused by RuII–arene m-Hoxonato tet-
ramers[15] or the DNA full-coiling induced by metallocylin-
ders.[12]
Experiments carried out at a lower DNA:2 mol ratio
(2.5:1) showed the formation of similar knotted aggregates
(Figure S14f), characterized by a higher surface density and
a slightly larger cross-sectional height (Supporting Informa-
tion), confirming a higher linear density of 2 bound to the
DNA strands. Conversely, a lower density of bridging
tetramers 2 was observed on incubating 5:1 DNA:2 samples
for 24 h at 310 K (Figures 3d and S14e, detailed discussion in
the Supporting Information). 1H NMR experiments demon-
strated that incubation caused cleavage of the tetranuclear
structure of these OsII complexes into dimers (Figures 2 and
S9), and can thus be expected to partially release plasmids
from the central core in the DNA-2 adducts, resulting in the
larger loops observed in Figure 3d. Both AFM experiments
were consistent with the dichroism measurements, indicating
that the changes in the CD and LD signals observed upon
increasing concentrations of 2 (Figures S11 and S13, respec-
tively) or incubating the 5:1 DNA:2 samples (Figure S13) are
probably due to a different extent of DNA condensation.
In conclusion, our studies reveal how the choice of spacer
length in tetranuclear organo-osmium metallacycles can
control their stability in solution and their biological activity,
which correlates with their ability to induce plasmid DNA
condensation. The more cytotoxic tetramer 1 reduces the
DNA negative charge significantly more than tetramer 2,
although the latter also exerts a considerable effect on DNA
structure. The different modes of interaction of 1 and 2 with
DNA seem likely to contribute to the large difference in
cytotoxicity exhibited by these candidate metallodrugs and
may play a role in their anticancer mechanism of action.
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Figure 3. AFM images of pBR322 plasmid DNA (a,b) in the absence,
and (c,d) the presence of 2·[PF6]4 in a DNA base:tetramer ratio of 5:1.
Images were recorded 30 min after preparing the samples (a, c) and
24 h after incubation at 310 K (b,d). OC=open-circular; L= linear
plasmid DNA. Conditions: 2 mm HEPES buffer, pH 7.2, 0.9 mm MgCl2,
[plasmid]=1.6 mgmL1.
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DNA and osmium tie the knot : Two OsII
tetranuclear metallacycle frameworks
constructed by linking inactive dihydrox-
ido arene dimers show significant differ-
ences in cytotoxicity against cancer cells
and behavior toward DNA condensation.
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